These agents, as well as the second-generation EGFR TKIs afatinib and dacomitinib and the third-generation EGFR TKI osimertinib have demonstrated superiority over chemotherapy for treating EGFR-mutated NSCLC as front-line therapy (6, 8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.